User profiles for Kenrick Ng
 | Kenrick NgConsultant in Medical Oncology, Bart's Health NHS Trust Verified email at ucl.ac.uk Cited by 740 |
Urinary biomarkers in bladder cancer: A review of the current landscape and future directions
K Ng, A Stenzl, A Sharma, N Vasdev - Urologic Oncology: Seminars and …, 2021 - Elsevier
… Kenrick Ng has received honoraria and travel grants from TESARO and GSK. Kenrick Ng
is currently funded by Cancer Research UK under a research grant under a Training …
is currently funded by Cancer Research UK under a research grant under a Training …
[HTML][HTML] Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting
K Ng, S Smith, J Shamash - Oncology and therapy, 2020 - Springer
The treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has
changed radically in recent years. Androgen deprivation therapy (ADT) alone was for decades …
changed radically in recent years. Androgen deprivation therapy (ADT) alone was for decades …
[HTML][HTML] Cardiovascular outcomes and hospitalizations in Asian patients receiving immune checkpoint inhibitors: a population-based study
Immune checkpoint inhibitors (ICI) have known associations with cardiotoxicity. However, a
representative quantification of the adverse cardiovascular events and cardiovascular …
representative quantification of the adverse cardiovascular events and cardiovascular …
[HTML][HTML] Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study
Background Although androgen deprivation therapy (ADT) is associated with cardiovascular
risks, the extent and temporal trends of cardiovascular burden amongst patients with …
risks, the extent and temporal trends of cardiovascular burden amongst patients with …
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
…, V Patel, MA Adas, F Atzeni, KKH Ng… - Annals of the …, 2023 - ard.bmj.com
Objectives To estimate the association of Janus kinase inhibitors (JAKi) with the incidence
of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and …
of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and …
Risk of new-onset prostate cancer for metformin versus sulfonylurea use in type 2 diabetes mellitus: a propensity score–matched study
Background: The aim of this study was to compare the risks of new-onset prostate cancer
between metformin and sulfonylurea users with type 2 diabetes mellitus (T2DM). Methods: This …
between metformin and sulfonylurea users with type 2 diabetes mellitus (T2DM). Methods: This …
[HTML][HTML] Biomarkers in bladder cancer surveillance
SS Sugeeta, A Sharma, K Ng, A Nayak… - Frontiers in …, 2021 - frontiersin.org
Aim: This is a narrative review with an aim to summarise and describe urinary biomarkers in
the surveillance of non-muscle-invasive bladder cancer (NMIBC). It provides a summary of …
the surveillance of non-muscle-invasive bladder cancer (NMIBC). It provides a summary of …
Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population‐based study
Background This study aims to examine the associations between metformin use concurrent
with androgen deprivation therapy (ADT) and mortality risks in Asian, diabetic patients with …
with androgen deprivation therapy (ADT) and mortality risks in Asian, diabetic patients with …
Prostate cancer disparities in risk group at presentation and access to treatment for Asian Americans, Native Hawaiians, and Pacific Islanders: a study with …
PURPOSE: We identified (1) differences in localized prostate cancer (PCa) risk group at
presentation and (2) disparities in access to initial treatment for Asian American, Native …
presentation and (2) disparities in access to initial treatment for Asian American, Native …
Long‐term prognostic impact of cardiovascular comorbidities in patients with prostate cancer receiving androgen deprivation therapy: a population‐based competing …
Our study investigated how adverse cardiovascular outcomes are impacted by cardiovascular
comorbidities in patients with prostate cancer treated by androgen deprivation therapy (…
comorbidities in patients with prostate cancer treated by androgen deprivation therapy (…